Abstract
Background: Epidermal growth factor receptor (EGFR) mutations are the most clinically actionable oncogenic drivers in Asian patients with non-small-cell lung cancer (NSCLC). The therapeutic landscape has rapidly evolved from single-agent EGFR tyrosine kinase inhibitors (TKIs) to risk-adapted first-line intensi...
R. Meng, Chun-Wei Xu, Wen-Xian Wang et al.· International Open Medical J...· 0 citations
BACKGROUND
Ruzaltatug rezetecan is a novel HER3-directed antibody-drug conjugate that has shown promising antitumour activity and manageable safety in pretreated EGFR-.mutated non-small-cell lung cancer (NSCLC) in a phase 1 trial. We aimed to compare the efficacy and safety of ruzaltatug rezetecan with chemotherapy in...
Chong-Rui Xu, Yan Zhang, G. Lin et al.· The Lancet· 1 citation
CRP and CEA hold the potential to predict the prognosis of advanced NSCLC patients undergoing first-line immunotherapy, with independent predictors for both progression-free survival and overall survival.
Peng Zhang, Peng Cao, Shan-Yue Tan et al.· Medicine· 0 citations
This review systematically summarizes the structure, mechanogating mechanisms, physiological and cellular functions of Piezo1, as well as its associations with human diseases.
Qixiang Wu, Ying Hu, Yuhan Wang et al.· Molecular Biomedicine· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.